Biosimilar monoclonal antibodies
Biosimilars and biobetters industry is likely to become a lot more dynamic and strategic than we’ve seen with small molecule generics; there will begin to become a premium on flexibility and willingness to take chances in an ever-shifting competitive and regulatory environment. The approval of the first biosimilar in the US is expected to save the healthcare industry and patients $5.7 billion over the next decade. The US biosimilars market is expected to reach $2 billion by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry.
- Biosimilars and Non-Originator Biologics
- Biosimilar Regime
- Use of Autologous IL-1ra and Other Cytokines in Orthopedics
- Technological Platform for Innovative and Biosimilar Antibodies
- Biosimilars and Non-Originator Biologics
- Novel Cell-Based Bioassays for Analysis of mAb Fc Effector and Immune Checkpoint
Related Conference of Biosimilar monoclonal antibodies
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
Biosimilar monoclonal antibodies Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibodies Immunogenecity
- Antibodies: Medical Applications
- Antibodies:Infectious Diseases
- Antibody Conjugate Therapeutics: Challenges and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Fragment Engineering and Applications in Diagnosis and Therapeutics
- Antibody Humanization Technologies
- Auto Antibodies
- Autoimmune Antibodies
- Bio therapeutics : Early Analytical Development
- Biomarkers Development
- Biosimilar monoclonal antibodies
- Biotherapeutics Antibody for the Treatment of Solid Cancers
- Biotherapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing (NGS) In Antibody Discovery and Engineering: Overview and Applications
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)